181 related articles for article (PubMed ID: 30445235)
1. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
2. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
5. Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia.
Rosenquist R; Thunberg U; Li AH; Forestier E; Lönnerholm G; Lindh J; Sundström C; Sällström J; Holmberg D; Roos G
Eur J Haematol; 1999 Sep; 63(3):171-9. PubMed ID: 10485272
[TBL] [Abstract][Full Text] [Related]
6. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
[TBL] [Abstract][Full Text] [Related]
8. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
[TBL] [Abstract][Full Text] [Related]
9. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
[TBL] [Abstract][Full Text] [Related]
10. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
[TBL] [Abstract][Full Text] [Related]
11. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement.
Maloum K; Pritsch O; Dighiero G
Hematol Cell Ther; 1997 Jun; 39(3):119-24. PubMed ID: 9262987
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
[TBL] [Abstract][Full Text] [Related]
14. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
[No Abstract] [Full Text] [Related]
15. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
17. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection.
Li AH; Rosenquist R; Forestier E; Lindh J; Roos G
Leuk Res; 2001 Dec; 25(12):1033-45. PubMed ID: 11684274
[TBL] [Abstract][Full Text] [Related]
18. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia.
Greenberg SJ; Choi Y; Ballow M; Du TL; Ward PM; Rickert MH; Frankel S; Bernstein SH; Brecher ML
J Leukoc Biol; 1995 Jun; 57(6):856-64. PubMed ID: 7790768
[TBL] [Abstract][Full Text] [Related]
19. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
[TBL] [Abstract][Full Text] [Related]
20. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]